Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) and Nutriband (NASDAQ:NTRB – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.
Profitability
This table compares Gyre Therapeutics and Nutriband’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gyre Therapeutics | -15.47% | -6.57% | -5.35% |
| Nutriband | -430.35% | -109.07% | -95.54% |
Valuation and Earnings
This table compares Gyre Therapeutics and Nutriband”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gyre Therapeutics | $116.59 million | 6.59 | $5.03 million | ($0.21) | -32.79 |
| Nutriband | $2.04 million | 35.29 | -$8.23 million | ($0.53) | -11.17 |
Gyre Therapeutics has higher revenue and earnings than Nutriband. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 52.2% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations and price targets for Gyre Therapeutics and Nutriband, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gyre Therapeutics | 2 | 0 | 1 | 0 | 1.67 |
| Nutriband | 1 | 1 | 0 | 0 | 1.50 |
Gyre Therapeutics currently has a consensus price target of $16.00, indicating a potential upside of 132.39%. Given Gyre Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Gyre Therapeutics is more favorable than Nutriband.
Risk & Volatility
Gyre Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, Nutriband has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.
Summary
Gyre Therapeutics beats Nutriband on 10 of the 14 factors compared between the two stocks.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
